转移性结直肠癌抗EGFR单抗获得性耐药的研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.05.012

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (5): 357-360.doi: 10.3760/cma.j.issn.1673-422X.2014.05.012

转移性结直肠癌抗EGFR单抗获得性耐药的研究进展

李敏敏,毕祥,王哲海

250117济南大学山东省医学科学院医学与生命科学学院;山东省肿瘤医院内三科

收稿日期:2013-12-23 修回日期:2014-01-10 出版日期:2014-05-08 发布日期:2014-04-28
通讯作者: 王哲海 E-mail:badgood007@126.com

Acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer

Li Minmin, Bi Xiang, Wang Zhehai

School of Medicine and Life Sciences,University of Ji′nanShandong Academy of Medicial Sciences; Department of Internal Medicine Ward 3, Shandong Cancer Hospital, Ji′nan 250117, China

Received:2013-12-23 Revised:2014-01-10 Online:2014-05-08 Published:2014-04-28
Contact: Wang Zhehai E-mail:badgood007@126.com

摘要/Abstract

摘要： 抗表皮生长因子受体单克隆抗体西妥昔单抗和帕尼单抗联合化疗是转移性结直肠癌治疗的常用药物，明显延长了患者生存期。然而，几乎所有接受抗表皮生长因子受体单抗治疗的患者都会出现耐药，而获得性耐药后目前没有标准治疗方案，因此探明获得性耐药的机制，并提出合理对策，有利于提高其疗效。

关键词: 结直肠肿瘤, 受体, 表皮生长因子, 抗体, 单克隆, 抗药性

Abstract: The combination of chemotherapy with antiepidermal growth factor receptor antibodies such as cetuximab and panitumumab which prolong the survival time in the past few years have been widely adopted for the treatment of metastatic colorectal cancer. However, a large number of patients develop resistance to these agents, while there is no standard treatment after acquired resistance yet. Therefore, finding out the mechanisms of acquired drug resistance and putting forward reasonable methods to overcome the acquired resistance will be improve its curative effect.

Key words: Colorectal neoplasms, Receptor, epidermal growth factor, Antibodies, monoclonal, Drug resistance

李敏敏,毕祥,王哲海. 转移性结直肠癌抗EGFR单抗获得性耐药的研究进展[J]. 国际肿瘤学杂志, 2014, 41(5): 357-360.

Li Minmin, Bi Xiang, Wang Zhehai. Acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer[J]. Journal of International Oncology, 2014, 41(5): 357-360.

参考文献

［1］ Bardelli A, Jnne PA. The road to resistence: EGFR mutation and cetuximab［J］. Nat Med, 2012, 18(2):199-200. ［2］ Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistence in colorectal cancer［J］. Nat Med, 2012, 18(2):221-223. ［3］ Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members［J］. Oncogene, 2008, 27(28):3944-3956. ［4］ Lu Y, Li X, liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistence escaping treatment by the antiEGFR monoclonal antibody cetuximab［J］. Cancer Res, 2007, 67(17):8240-8247. ［5］ Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to antiEGFR therapy in colorectal cancer［J］. Nature, 2012, 486(7404):532-536. ［6］ Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquiredresistance to targeted EGFR blockade in colorectal cancers［J］. Nature, 2012, 486(7404):537-540. ［7］ Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab［J］. Cancer Biol Ther, 2011, 11(9):777792. ［8］ Ciardiello F, Bianco R, Caputo R. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy［J］. Clin Cancer Res, 2004, 10(2):784-793. ［9］ Vallbhmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy［J］. J Clin Oncol, 2005, 23(15):3536-3544. ［10］ Li C, Iida M, Dunn EF, et al. Nuclear EGFR contributes to acquired resistence to cetuximab［J］. Oncogene, 2009, 28(43):3801-3813. ［11］ OliverasFerraros C, Massaguer VallLlovera A, Carrion Salip D, et al. Evolution of the predictive markers amphiregulin and epiregulin mRNA during long term cetuximab treatment of KRAS wild type tumor cells［J］. Invest New Drugs, 2012, 30(2):846-852. ［12］ Kim SM, Kim JS, Kim JH, et al. Acquired resistance to cetuximab is mediated by increased PTEN instability and lead crossresistance to gefitinib in HCC827 NSCLC cells［J］. Cancer Lett, 2010, 296(2):150159. ［13］ Wheeler DL, Lida M, Kruser TJ, et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab［J］. Cancer Biol Ther, 2009, 8(8):696-703. ［14］ Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?［J］. Ann Oncol, 2012, 23(9):2313-2318. ［15］ Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer［J］. J Clin Oncol, 2008, 26(14):2311-2319. ［16］ Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer［J］. N Engl J Med, 2004, 351(4):337-334. ［17］ Matar P, Rojo F, Cassia R. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMGC225): superiority over singleagent receptor targeting［J］. Clin Cancer Res, 2004, 10(19):6487-6501. ［18］ Dunn EF, Iida M, Myers RA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab［J］. Oncogene, 2011, 30(5):561-574. ［19］ Garrett JT, Arteaga CL. Resistance to HER2directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications［J］. Cancer Biol Ther, 2011,11(9):793-800. ［20］ Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international,multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863):303-312.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[5]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[8]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[9]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[10]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[11]	秦雪倩, 杨宏宇, 王真, 王孟超, 张欣. 双特异性抗体在非小细胞肺癌治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(9): 558-563.
[12]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[13]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[14]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[15]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.

转移性结直肠癌抗EGFR单抗获得性耐药的研究进展

Acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价